Tranexamic acid: Less bleeding and less thrombosis?

Critical Care

Volumn 16, Issue 3, 2012, Pages

  Godier, Anne ^a,b   Roberts, Ian ^c   Hunt, Beverley J ^b,d  

^a HÔTEL DIEU   (France)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ENOLASE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; LEUKOTRIENE; LIPOCORTIN 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMIN; PROSTACYCLIN; TRANEXAMIC ACID; UROKINASE RECEPTOR; VON WILLEBRAND FACTOR; ANTIFIBRINOLYTIC AGENT; PLASMINOGEN;

ANTIINFLAMMATORY ACTIVITY; ARTERY REOCCLUSION; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; CARDIOPULMONARY BYPASS; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; ELECTIVE SURGERY; FIBRINOLYSIS; HEART INFARCTION; HUMAN; INFLAMMATION; INJURY; MACROPHAGE MIGRATION; MORTALITY; NOTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; HEMORRHAGE;

ANTIFIBRINOLYTIC AGENTS; FACTOR V; FACTOR VIII; FIBRINOLYSIN; HEMORRHAGE; HUMANS; PLASMINOGEN; PLATELET ACTIVATION; TRANEXAMIC ACID; WOUNDS AND INJURIES;

EID: 84863202667     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11374     Document Type: Note

References (19)

1. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012, 344:e3054. 10.1136/bmj.e3054, 3356857, 22611164.
2. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. CRASH-2 collaborators The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011, 377:1096-1101. 1101.e1-2, CRASH-2 collaborators.
3. Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet JF. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 2008, 64:1211-1217. discussion 1217, 10.1097/TA.0b013e318169cd3c, 18469643.
4. Jimenez JJ, Iribarren JL, Lorente L, Rodriguez JM, Hernandez D, Nassar I, Perez R, Brouard M, Milena A, Martinez R, Mora ML. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care 2007, 11:R117. 10.1186/cc6173, 2246206, 17988379.
5. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004, 351:2611-2618. 10.1056/NEJMoa041747, 15602021.
6. Ng JL, Chan MT, Gelb AW. Perioperative stroke in noncardiac, nonneurosurgical surgery. Anesthesiology 2011, 115:879-890. 10.1097/ALN.0b013e31822e9499, 21862923.
7. Laumonnier Y, Syrovets T, Burysek L, Simmet T. Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes. Blood 2006, 107:3342-3349. 10.1182/blood-2005-07-2840, 16373665.
8. Wygrecka M, Marsh LM, Morty RE, Henneke I, Guenther A, Lohmeyer J, Markart P, Preissner KT. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood 2009, 113:5588-5598. 10.1182/blood-2008-08-170837, 19182206.
9. Lighvani S, Baik N, Diggs JE, Khaldoyanidi S, Parmer RJ, Miles LA. Regulation of macrophage migration by a novel plasminogen receptor Plg-R KT. Blood 2011, 118:5622-5630. 10.1182/blood-2011-03-344242, 21940822.
10. Burysek L, Syrovets T, Simmet T. The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. J Biol Chem 2002, 277:33509-33517. 10.1074/jbc.M201941200, 12093796.
11. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987, 76:142-154. 10.1161/01.CIR.76.1.142, 3109764.
12. Quinton TM, Kim S, Derian CK, Jin J, Kunapuli SP. Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem 2004, 279:18434-18439. 10.1074/jbc.M401431200, 14973136.
13. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brückner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010, 185:5628-5636. 10.4049/jimmunol.0903678, 3123139, 20870944.
14. Ogiwara K, Nogami K, Nishiya K, Shima M. Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII. Blood Coagul Fibrinolysis 2010, 21:568-576. 10.1097/MBC.0b013e32833c9a9f, 20625277.
15. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989, 73:185-190.
16. Nogami K, Shima M, Matsumoto T, Nishiya K, Tanaka I, Yoshioka A. Mechanisms of plasmin-catalyzed inactivation of factor VIII: a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation. J Biol Chem 2007, 282:5287-5295.
17. Li A, Wun TC. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Thromb Haemost 1998, 80:423-427.
18. Stalboerger PG, Panetta CJ, Simari RD, Caplice NM. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor. Thromb Haemost 2001, 86:923-928.
19. Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005, 173:627-634. doi:10.1186/cc11374, 10.1503/cmaj.050011, 1197163, 16157727.